Idalman

Olmesartan medoxomil, the active ingredient in Idalman, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Idalman as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil belongs to the class of Angiotensin II receptor blockers and is indicated for conditions related to elevated blood pressure.

Hypertension: lowers systolic and diastolic blood pressure in patients with primary (essential) hypertension, helping to reduce cardiovascular risk.

Adverse reactions may occur with any medication. The following lists reported events associated with olmesartan medoxomil.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Abdominal discomfort - Elevated blood potassium levels

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Acute renal failure or worsening kidney function - Severe hyperkalemia - Hepatic injury or jaundice

Before initiating therapy, certain safety considerations should be reviewed. - Blood pressure monitoring: check regularly to ensure therapeutic effect and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Serum potassium: monitor for hyperkalemia, particularly when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with severe liver disease. - Pregnancy and lactation: avoid use during pregnancy; safety in breastfeeding is unknown. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment: combined use may increase risk of renal dysfunction. - Concurrent ACE inhibitor or another ARB: may cause excessive potassium rise and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Lithium: olmesartan may increase lithium levels, necessitating serum monitoring. - NSAIDs (e.g., ibuprofen): can attenuate antihypertensive response and affect renal function.